Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
ApexOnco Front Page
Recent articles
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
AVZO-023 follows AVZO-021 into clinical trials.
